Targeted Oncology

, Volume 7, Issue 2, pp 127–133 | Cite as

Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib

  • Sandrine Faivre
  • Maxime Ronot
  • Chantal Dreyer
  • Camille Serrate
  • Olivia Hentic
  • Mohamed Bouattour
  • Onorina Bruno
  • Anne Couvelard
  • Valérie Vilgrain
  • Eric Raymond


Among neuroendocrine carcinomas of the gut, well-differentiated tumors are highly vascularized, featuring specific characteristics on contrast-enhanced imaging. Well-differentiated neuroendocrine tumors spontaneously harbor hypervascular enhancement, coexisting with areas of necrosis mainly located at the center of tumor lesions. When exposed to vascular endothelial growth factor (VEGFR) inhibitors such as sunitinib, target lesions display few if any variation in tumor size, but rather detectable modifications in tumor density. In several patients treated with targeted therapy, a significant decrease of tumor density at first tumor evaluation can be detected as compared to baseline. Consistently, the two randomized trials leading to approval of sunitinib and everolimus in pancreatic neuroendocrine tumors report objective response rate below 10 %, emphasizing that Response Evaluation Criteria in Solid Tumors (RECIST), that focus only on the largest diameters of target lesions, may be insufficient to capture the full benefit of targeted therapies. Alternative criteria, such as those developed by Choi et al., consider both the size and the density of the tumor as parameters for response evaluation. Choi criteria have been recently proposed as a surrogate endpoint for efficacy and to identify patients that are good responders to VEGFR inhibitors such as sunitinib and sorafenib in advanced hepatocellular carcinoma, another disease highly addicted to angiogenesis. Preliminary data generated from patients included in the sunitinib phase III trial suggest that Choi criteria might also be considered as an alternative to RECIST to evaluate the effects of sunitinib in patients with advanced well-differentiated neuroendocrine tumors.


RECIST Choi Angiogenesis Hypodensity Necrosis 


Conflicts of interest

All authors of this manuscript have no conflicts of interest except for Sandrine Faivre and Eric Raymond who were compensated with honorarium from Pfizer and Novartis.


  1. 1.
    Joensuu H, Roberts PJ, Sarlomo-Rikala M et al (2001) Effect of the tyrosine kinase inhibitor STI-571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344:1052–1056PubMedCrossRefGoogle Scholar
  2. 2.
    Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216PubMedCrossRefGoogle Scholar
  3. 3.
    Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247PubMedCrossRefGoogle Scholar
  4. 4.
    Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124PubMedCrossRefGoogle Scholar
  5. 5.
    Verweij J, Casali PG, Zalcberg J et al (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364:1127–1134PubMedCrossRefGoogle Scholar
  6. 6.
    Blanke CD, Rankin C, Demetri GD et al (2008) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26:626–632PubMedCrossRefGoogle Scholar
  7. 7.
    Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390PubMedCrossRefGoogle Scholar
  8. 8.
    Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL et al (2007) We should desist using RECIST, at least in GIST. J Clin Oncol 25:1760–1764PubMedCrossRefGoogle Scholar
  9. 9.
    Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR et al (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25:1753–1759PubMedCrossRefGoogle Scholar
  10. 10.
    Faivre S, Sablin MP, Dreyer C, Raymond E (2010) Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumors. Endocrinol Metab Clin N Am 39:811–826CrossRefGoogle Scholar
  11. 11.
    Raymond E et al (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501–513PubMedCrossRefGoogle Scholar
  12. 12.
    Yao JC et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514–523PubMedCrossRefGoogle Scholar
  13. 13.
    Couvelard A et al (2005) Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br J Cancer 92:94–101PubMedCrossRefGoogle Scholar
  14. 14.
    Rodallec M et al (2006) Endocrine pancreatic tumours and helical CT: contrast enhancement is correlated with microvascular density, histoprognostic factors and survival. Pancreatology 6:77–85PubMedCrossRefGoogle Scholar
  15. 15.
    Dromain C, de Baere T, Lumbroso J et al (2005) Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol 23:70–78PubMedCrossRefGoogle Scholar
  16. 16.
    Faivre S et al (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25–35PubMedCrossRefGoogle Scholar
  17. 17.
    Faivre S, Demetri G, Sargent W, Raymond E (2007) Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 6:734–745PubMedCrossRefGoogle Scholar
  18. 18.
    Faivre S, Raymond E, Boucher E et al (2009) Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol 10:794–800PubMedCrossRefGoogle Scholar
  19. 19.
    Faivre S, Zappa M, Vilgrain V, Boucher E, Douillard JY, Lim HY, Kim JS, Im SA, Kang YK, Bouattour M, Dokmak S, Dreyer C, Sablin MP, Serrate C, Cheng AL, Lanzalone S, Lin X, Lechuga MJ, Raymond E (2011) Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib. Clin Cancer Res 17:4504–4512PubMedCrossRefGoogle Scholar
  20. 20.
    Faivre SJ, Bouattour M, Dreyer C, Raymond E (2009) Sunitinib in hepatocellular carcinoma: redefining appropriate dosing, schedule, and activity end points. J Clin Oncol 27:e248–e250PubMedCrossRefGoogle Scholar
  21. 21.
    Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA et al (2009) Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 27:3027–3035PubMedCrossRefGoogle Scholar
  22. 22.
    Desar IM, van Herpen CM, van Laarhoven HW, Barentsz JO, Oyen WJ, van der Graaf WT (2009) Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy. Cancer Treat Rev 35:309–321PubMedCrossRefGoogle Scholar
  23. 23.
    Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24:4293–4300PubMedCrossRefGoogle Scholar
  24. 24.
    Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK et al (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35:421–430PubMedCrossRefGoogle Scholar
  25. 25.
    Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30:52–60PubMedCrossRefGoogle Scholar
  26. 26.
    Wassermann J, Bouattour M, Bruno O, Serrate C, Larroque B, Castera L, Dreyer C, Sablin MP, Colichi C, Vilgrain V, Belghiti J, Raymond E, Faivre S (2011) Blinded independent central response assessment using RECIST, mRECIST, and Choi criteria in patients treated with sorafenib for advanced hepatocellular carcinoma (HCC). Proc ILCA MeetingGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Sandrine Faivre
    • 1
    • 5
  • Maxime Ronot
    • 2
  • Chantal Dreyer
    • 1
  • Camille Serrate
    • 1
  • Olivia Hentic
    • 3
  • Mohamed Bouattour
    • 1
  • Onorina Bruno
    • 2
  • Anne Couvelard
    • 4
  • Valérie Vilgrain
    • 2
  • Eric Raymond
    • 1
  1. 1.Department of Medical OncologyBeaujon University Hospital (AP-HP–Paris 7 Diderot)ClichyFrance
  2. 2.Department of RadiologyBeaujon University Hospital (AP-HP–Paris 7 Diderot)ClichyFrance
  3. 3.Department of Gastroenterology and PancreatologyBeaujon University Hospital (AP-HP–Paris 7 Diderot)ClichyFrance
  4. 4.Department of PathologyBichat University HospitalParisFrance
  5. 5.Department of Medical Oncology (INSERM U728–PRES Paris 7 Diderot), Assistance Publique–Hôpitaux de ParisBeaujon University HospitalClichyFrance

Personalised recommendations